Company News-Guangzhou DiQi Pharmaceuticals Co., Ltd

Home

About Us

Technology Platform

Product Center

Service and Support

Collaboration Mode

News

Join Us

News

Company News

Filter:

All years

All years 2017 2018 2019 2020 2021 2022 2023 2024 2025

2020/04/10DiQi Pharma Supports Guizhou Tian’an Pharma’s Glimepiride Tablets (2mg) in Passing Generic Drug Consistency Evaluation

On April 7, 2020, Guizhou Tian'an Pharma and its parent company Boya Biotech Co., Ltd. jointly announced that Guizhou Tian'an Pharma's glimepiride tablets (2mg dosage) had passed the consistency evaluation for generic drug quality and efficacy. The company received the “Supplemental Application Approval Document” issued by the National Medical Products Administration.
2020/03/30Great news! DiQi Pharma’s First Biodegradable Material PLGA (8515) Successfully Registered with CDE

DiQi Pharma's first biodegradable material, L-lactide-L-glycolide copolymer (8515) (for injection), was successfully registered with the CDE on March 27, 2020, marking the first domestic registration of this product. DiQi Pharma promptly submitted a registration application for L-lactide-L-glycolide copolymer (7525) (for injection) and plans to submit another application for L-lactide-L-glycolide copolymer (5050) (for injection) this year.
2020/03/16Warm Congratulations to DiQi Pharma for Being Selected as a “Two High, Four New” Enterprise in Guangzhou

On March 12, 2020, DiQi Pharma was selected as a “Two Highs and Four News” enterprise. This recognition by the Guangzhou Municipal Commission of Industry and Information Technology affirms DiQi Pharma's development direction and achievements.
2019/12/05DiQi Pharma Paves the Way for Students' Future

On the morning of December 1st, DiQi Pharma welcomed first-year students from Class 2 of the Biomedical Engineering program at South China University of Technology. The students toured the pharmaceutical R&D laboratories, including the analytical laboratory and the formulation laboratory.
2019/11/07Leaders from Zhenbao Island Pharmaceutical Group Visit DiQi Pharma

On November 5, Fang Tonghua, Chairman of Zhenbaodao Group, led relevant executives and experts from the group on a visit to DiQi Pharmaceuticals Co., Ltd. They engaged in in-depth discussions on projects and technologies with DiQi Pharmaceuticals Co., Ltd.'s senior management team and project leaders. Zhang Ling, Executive Vice President of DiQi Pharma, and Dr. Peng Tangsheng, Vice President, respectively introduced the company's overview and quality system, and guided the delegation on a tour of the laboratory and office areas.
2019/11/06DiQi Pharma Supports Harbin Pharmaceutical Group’s Sixth Factory Metformin Hydrochloride Tablets (0.25g) in Passing Generic Drug Consistency Evaluation

On October 21, 2019, Harbin Pharmaceutical Group announced that its subsidiary, Harbin Pharmaceutical Group Sixth Pharmaceutical Factory (hereinafter referred to as “HPG Sixth Factory”), had successfully passed the consistency evaluation for the quality and efficacy of its generic metformin hydrochloride tablets. The product received the “Supplemental Application Approval Document” issued by the National Medical Products Administration.
2019/10/17DiQi Pharma Honored as a “Top 50 Pioneer Biotech Enterprise in the Greater Bay Area (2nd Edition)”

On October 16, the Bio-Tech Innovation Enterprise Exchange Summit and the Second Bay Area Top 50 Awards Ceremony were grandly held in Nansha, Guangzhou. Guangzhou DiQi Pharmaceuticals Co., Ltd was once again honored with the title of “Second Guangdong-Hong Kong-Macao Greater Bay Area Top 50 Bio-Tech Innovation Enterprises”!
2019/08/27“Prevent Risks, Eliminate Hazards, Curb Accidents” - DiQi Pharma Conducts 2019 Annual Safety Training and Evacuation Drill

In active response to the theme of the 2019 National Work Safety Month—“Prevent Risks, Eliminate Hazards, Curb Accidents”—and to effectively enhance the safety awareness and competence of all employees while improving disaster prevention, mitigation, and relief capabilities, our company conducted its annual safety knowledge training and evacuation drill on August 23.

1 2 3 4 5

Contact Information

Address:8 Luoxuan 3rd Road, Guangzhou International BIO-island

Main telephone number:020-32227031

Fax:020-32227031

Email:gzdq@gzdqyy.com
Customer Service

Postal Code:510300

Business Consulting:18122367150 13602749876

Complaints Hotline:020-32227031

Complaint Email:diqiyjx@gzdqyy.com

Official WeChat

top